drugset / Trial / NCT04761198
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
Non-randomizedParallel-groupOpen-labelBasic science
Summary
This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of etigilimab in combination with nivolumab in participants with locally advanced or metastatic solid tumors. Participants will be assigned to receive etigilimab (every 2 weeks) in combination with nivolumab (240 milligrams \[mg\] every 2 weeks).
Timeline
- Start
- 2021-03-23
- Primary completion
- 2023-10-30
- Completion
- 2023-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etigilimab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |